Target intelligence / Profile preview

Short stature homeobox protein (SHOX)

Target
SHOX
Molecular classification
Transcription factor, Homeobox protein
01

Overview

The short stature homeobox protein (SHOX) is a transcription factor encoded by the SHOX gene, located in the pseudoautosomal region of both the X and Y chromosomes. SHOX helps control the expression of other genes, particularly during early embryonic development, where it is essential for normal skeletal formation and the growth/maturation of bones, especially in the arms and legs. It maintains bone progenitor cell populations and regulates the timing of osteogenic differentiation. Mutations, deletions, or dosage changes in SHOX lead to several congenital disorders, notably Turner syndrome, Léri-Weill dyschondrosteosis, Langer mesomelic dysplasia, and idiopathic short stature. SHOX is a member of the homeobox gene family and acts as a transcriptional activator or repressor depending on the cellular context. No clinically approved drugs directly target SHOX, and its primary relevance is as a diagnostic biomarker for skeletal dysplasia syndromes. Its therapeutic targeting, safety issues, and mechanism of action for drugs are currently not applicable given its role.

Other names
Short-stature homeobox geneSHOX homeoboxGCFXPHOGSHOX1SHOXYSSShort stature homeobox proteinGrowth control factor, X-linkedPseudoautosomal homeobox-containing osteogenic proteinShort stature homeoboxSHOX
02

Mechanism of action

Not applicable; no known drugs directly target SHOX.

03

Biological functions

Regulation of gene transcription during early embryonic developmentRegulation of skeletal development (especially bones in arms and legs)Regulation of cell proliferation in skeletal progenitor cellsNegative regulation of early osteogenic differentiation
04

Disease associations

Turner syndrome (related to haploinsufficiency)Léri-Weill dyschondrosteosis (single gene mutation)Langer mesomelic dysplasia (mutation/deletion in both copies)Idiopathic short statureOther skeletal dysplasias
05

Safety considerations

Not applicable for therapeutics; however, genetic loss or mutation of SHOX leads to serious congenital skeletal disorders including very short stature, bone deformities, and growth deficits
06

Biomarkers

Loss or mutation of SHOX is a diagnostic biomarker for Turner syndrome, Léri-Weill dyschondrosteosis, and Langer mesomelic dysplasia

Beyond the preview

Go deeper on Short stature homeobox protein (SHOX).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Short stature homeobox protein (SHOX).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call